Holen Sie sich die Stockscreener-App
1.51
1.95%
-0.03
Handel nachbörslich:
1.50
-0.01
-0.66%
Biomea Fusion Inc Aktie (BMEA) Neueste Nachrichten
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion (BMEA) awards 452,512 stock options to director and officer Erdtmann - stocktitan.net
Biomea Fusion (BMEA) interim CEO awarded 667,477 options at $1.49 strike - stocktitan.net
Icovamenib development timeline includes Phase II updates and 52-week data in 2026 - Traders Union
BMEA Technical Analysis & Stock Price Forecast - Intellectia AI
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies - The Manila Times
Patients failing standard diabetes drugs enter 2 Biomea studies - stocktitan.net
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts - MarketBeat
Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes - MarketBeat
Biomea Fusion reports 24 percent jump in insulin secretion in Phase 2 Icovamenib study - Traders Union
Analysts sentiment on Biomea Fusion (BMEA) remains strong amid strong diabetes trial results - MSN
Is Biomea Fusion Inc stock a good pick for beginners2026 PostEarnings & Weekly High Return Stock Forecasts - baoquankhu1.vn
Biomea Fusion (NASDAQ:BMEA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Biomea Fusion (NASDAQ:BMEA) Price Target Raised to $7.00 at Citigroup - MarketBeat
HC Wainwright Comments on Biomea Fusion Q1 Earnings - MarketBeat
Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth? - Yahoo Finance
Biomea Fusion prioritizes key data delivery for clinical programs - Traders Union
Biomea Fusion Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results - Insider Monkey
Biomea Fusion 2025 Financial Report - AlphaStreet
Biomea Fusion's (BMEA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Aug Shorts: Can Biomea Fusion Inc ride the EV wave2026 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
Biomea Fusion, Inc. 2025 Annual Report: Advancing Oral Diabetes & Obesity Therapies with Innovative Small Molecule Drugs - Minichart
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights - Bitget
Biomea Fusion (NASDAQ:BMEA) Issues Earnings Results - MarketBeat
Biomea 10-K: $0 Revenue, $(1.18) EPS; net loss narrows to $(61.80)M - TradingView
BMEA: Clinical progress in diabetes and obesity, reduced net loss, and strong cash position into 2027 - TradingView
Biomea Fusion (NASDAQ: BMEA) highlights icovamenib Phase II data - Stock Titan
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Biomea Fusion (BMEA) cuts 2025 loss as icovamenib and GLP‑1 obesity programs advance - Stock Titan
Biomea Fusion targets new partnerships and investor interest at BIOEurope2026 - Traders Union
Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Monday - MarketBeat
If You Invested $1,000 in Biomea Fusion, Inc. (BMEA) - stocktitan.net
BMEA SEC FilingsBiomea Fusion, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Street Watch: Is Biomea Fusion Inc stock overvalued or fairly priced2026 Closing Moves & Verified Momentum Stock Watchlist - baoquankhu1.vn
Heights Capital Management Inc. Reduces Stock Holdings in Biomea Fusion, Inc. $BMEA - MarketBeat
Why Is Biomea Fusion (BMEA) Stock Down 63% Today? - TradingView
Biomea Fusion, Inc. (BMEA) Presents at 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026Slideshow (NASDAQ:BMEA) 2026-03-16 - Seeking Alpha
Biomea Fusion Presents Positive Phase II COVALENT-111 Data in Type 2 Diabetes - National Today
Juan Pablo Frias presents diabetes research for Biomea Fusion at ATTD 2026 - Traders Union
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib - Benzinga
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 - The Manila Times
Biomea Fusion Reports Positive 52-Week Results for Icovamenib in Type 2 Diabetes at ATTD 2026 Conference - Quiver Quantitative
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 - GlobeNewswire
D. Boral Capital Maintains Biomea Fusion (BMEA) Buy Recommendation - MSN
Biomea Fusion Details Diabetes, Obesity Pipeline at Citizens Conference, Sees Cash Runway to Q1 2027 - MarketBeat
Biomea Fusion, Inc. (BMEA) Presents at The Citizens Life Sciences Conference 2026Slideshow - Seeking Alpha
Aug Fed Impact: Can Biomea Fusion Inc sustain its profitabilityMarket Movers & Risk Managed Investment Entry Signals - baoquankhu1.vn
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biomea Fusion to present icovamenib clinical data at ATTD 2006 - Traders Union
Biomea Fusion : Presentation Citizens Life Sciences Conference March 2026 - marketscreener.com
Icovamenib advances drive optimism for diabetes cure, Biomea Fusion asserts - Traders Union
Biomea Fusion (BMEA) Price Target Decreased by 10.64% to 7.14 - MSN
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):